LDT

Guardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance

Retrieved on: 
Donnerstag, Mai 9, 2024
Software, Professional Services, Pharmaceutical, Oncology, Technology, Genetics, Artificial Intelligence, Health Technology, Data Analytics, Clinical Trials, Biotechnology, FDA, Health, Net, LDT, Depreciation, Webcast, Forecasting, Helmy Eltoukhy, Patient, Medicare, Marketing, GAAP, Growth

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2024.

Key Points: 
  • Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2024.
  • Development services and other revenue was $12.3 million for the first quarter of 2024, compared to $15.3 million for the corresponding prior year period.
  • Precision oncology gross margin was 62% in the first quarter of 2024, as compared to 60% in the prior year period.
  • Guardant Health will host a conference call to discuss the first quarter 2024 financial results after market close on Thursday, May 9, 2024 at 1:30 pm Pacific Time / 4:30 pm Eastern Time.

T2 Biosystems Announces Letter of Intent to Enter Strategic Partnership for Lyme Disease

Retrieved on: 
Dienstag, Mai 7, 2024
Infection, FDA, Notifiable disease, United, Disease, Public health, LDT, Publication, Bacteria, MD, Clinical Laboratory, Partnership, Research, CLIA, Borrelia burgdorferi, Lyme disease, Laboratory developed test, ECO, Diagnosis, Antibody, Prospectus, Journal, Vaccine

LEXINGTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has signed a non-binding letter of intent (“LOI”) to enter into a strategic partnership with ECO Laboratory, a Massachusetts-based clinical laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA).

Key Points: 
  • ECO Laboratory was founded by Karen Weeks, who has been at the forefront of Lyme disease research and testing for decades.
  • Weeks developed the Lyme Antibody Capture Immunoassay, which remains one of the most sensitive serology tests available for Lyme disease.
  • Lyme disease is the leading vector-borne disease in America, with an estimated 3.4 million tests performed each year.
  • Although early symptoms of Lyme disease are similar to the flu, Borrelia burgdorferi infections can lead to chronic, debilitating disease.

Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business

Retrieved on: 
Dienstag, Mai 7, 2024
Prostate, MYGN, LDT, Myriad Genetics, Breast, Genetic testing, Genetics, Cancer, Patient, Myriad, Laboratory developed test, Medicine

As part of the reorganization, Myriad signed a definitive agreement to sell its EndoPredict® business to Eurobio Scientific, a leading French group in in vitro medical diagnostics and life sciences.

Key Points: 
  • As part of the reorganization, Myriad signed a definitive agreement to sell its EndoPredict® business to Eurobio Scientific, a leading French group in in vitro medical diagnostics and life sciences.
  • Myriad will also license Eurobio the right to sell Prolaris in vitro diagnostic kits outside the U.S.
  • “The change in our international strategy is part of our continued effort to accelerate profitable growth while supporting our biopharma partners in the most efficient manner,” said Paul J. Diaz, president and CEO of Myriad Genetics.
  • “By divesting the EndoPredict business to Eurobio, we believe EndoPredict and our European teammates will have more opportunities to grow given Eurobio’s strength and presence in the European market.

Companion Diagnostics Technologies and Global Markets Report 2023-2024 and 2028 Featuring Major Players - F. Hoffmann-La Roche, Agilent Technologies, and QIAGEN - ResearchAndMarkets.com

Retrieved on: 
Freitag, Mai 3, 2024
General Health, Health, Pharmaceutical, Clinical Trials, Oncology, Cancer, Agilent Technologies, LDT, Market, Exosome, QIAGEN, Immunohistochemistry, Polymerase chain reaction, DSM-IV codes, Intelligence, SRL Diagnostics, ChromeOS, Patent, ESG, CDX, Infection, Cardiovascular disease

The current report provides detailed coverage of the companion diagnostics market.

Key Points: 
  • The current report provides detailed coverage of the companion diagnostics market.
  • This report highlights the current and future market potential of companion diagnostics, and it includes a detailed analysis of the drivers, opportunities, restraints, and challenges in the market.
  • The report details the companion diagnostics market share based on product and service, type of test, technology, and application.
  • Company profiles of major players within the industry, including F. Hoffmann-La Roche Ltd., Agilent Technologies Inc., and QIAGEN

TIME Selects ALZpath Co-Founder Dr. Venkat Shastri As Inaugural Member of Time100 Health Ranking

Retrieved on: 
Donnerstag, Mai 2, 2024
Diagnosis, Risk, LDT, Chairperson, MD, PET, Doctor of Philosophy, Time (magazine), JAMA Neurology, Research, Entrepreneurship, TIME, Patient, Health, Dementia, Global health

CARLSBAD, Calif., May 2, 2024 /PRNewswire/ -- ALZpath, Inc., a leading developer of innovative diagnostic tools and solutions for Alzheimer's disease and related dementias, announced today that TIME Magazine has named ALZpath's Co-Founder and CEO, Venkat Shastri, PhD, to the inaugural TIME100 Health list. This annual list recognizes the impact, innovation, and achievement of 100 of the world's most influential individuals who most impacted global health this year. 

Key Points: 
  • This annual list recognizes the impact, innovation, and achievement of 100 of the world's most influential individuals who most impacted global health this year.
  • Dr. Shastri co-founded ALZpath with Eric Reiman, MD and Jerre Stead, driven by a mission to transform the diagnosis, treatment and management of Alzheimer's disease.
  • "I am honored to be listed among TIME100's health leaders and applaud their dedication to enhancing healthcare outcomes around the world," said Venkat Shastri, PhD, Co-Founder and CEO of ALZpath.
  • The test, known as ALZpath Dx, is currently available as a laboratory developed test (LDT) for clinical diagnostic use and clinical trials.

Thermo Fisher Scientific Launches New CXCL10 Testing Service

Retrieved on: 
Donnerstag, Mai 2, 2024
Research, General Health, Pharmaceutical, Oncology, Medical Devices, Hospitals, Science, Surgery, Biotechnology, Medical Supplies, Other Science, Health, Mortality, FDA, Inflammation, Health equity, Risk, Organ transplantation, LDT, Immunosuppression, Collection, CLIA, Thermo Fisher Scientific, Patient, Mental health, CXCL10, Quality of life, Disease, Medical device

Thermo Fisher Scientific One Lambda Laboratories, a CLIA facility in Fishers, Ind., has introduced a new CXCL10 testing service, which allows for non-invasive urine sample collection and testing, with results available in as little as 24 hours, providing valuable information faster than currently used tests.

Key Points: 
  • Thermo Fisher Scientific One Lambda Laboratories, a CLIA facility in Fishers, Ind., has introduced a new CXCL10 testing service, which allows for non-invasive urine sample collection and testing, with results available in as little as 24 hours, providing valuable information faster than currently used tests.
  • In keeping with our commitment to health equity, we believe this lower-cost, non-invasive testing option can expand access to care and improve patient adherence, since the sample can be collected at any local clinic,” says Chris McCloskey, director, Transplant Services, Thermo Fisher Scientific.
  • Thermo Fisher’s CXCL10 testing service may supplement current standards of care that may lack specificity or sensitivity, which may lead to unnecessary and invasive biopsies, or produce results too late to influence care, making treating rejection more difficult.
  • The Thermo Fisher One Lambda Laboratories CXCL10 assay was developed and validated by One Lambda Laboratories.

Usual Labs Announces a Strategic Funding Round of $7M and $75M TVL Committed to Compete With Stablecoin Giants

Retrieved on: 
Mittwoch, April 17, 2024
Kraken, Ethereum, Element, TVL, News, LDT, Fintech, Member of Congress, Breed, StarkWare Industries, Entrepreneurship, National Assembly, Trust, GSR, Human, Philosophy, Growth, Labs, Cryptocurrency

PARIS, April 17, 2024 /PRNewswire/ -- Usual Labs, the company in charge of developing Usual, an innovative protocol bridging the gap between traditional and decentralized finance through the USD0 stablecoin, is proud to announce that it has raised $7M and committed $75M in Total Value Locked (TVL) to ensure its launch in Q2 2024. Usual Labs has garnered the support of more than a hundred investors, including two leading co-investors, IOSG Ventures and Kraken Ventures, as well as a diverse group of notable investors, including GSR, Mantle, StarkWare, Flowdesk, Avid3, Bing Ventures, Breed, Hypersphere, Kima Ventures, Psalion, Public Works, and X Ventures.

Key Points: 
  • With its innovative Liquid Deposit Token (LDT), Usual is aiming to establish itself as the leading DeFi-native stablecoin.
  • Acknowledging the demand for a stablecoin that is secure and owned by the community, Usual Labs has brought together a majority of founders from the DeFi ecosystem.
  • The fundraising will allow Usual Labs to prepare for the pre-launch of the USD0 stablecoin on the Ethereum mainnet in Q2 2024.
  • The team's unmatched expertise in regulation, operations, and DeFi, spearheaded by Pierre Person, positions Usual uniquely to capitalize on their vision."

T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates

Retrieved on: 
Mittwoch, März 20, 2024
Sepsis, Development, Lyme disease, Growth, Panel, International, Laboratory, Instrument, LDT, ASPR, Journal of Clinical Microbiology, Pharmaceutical industry

LEXINGTON, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans for the T2Lyme Panel commercial launch and provided recent business updates.

Key Points: 
  • LEXINGTON, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans for the T2Lyme Panel commercial launch and provided recent business updates.
  • The Company is currently in discussions with potential LDT partners and plans to provide early Lyme disease results to U.S. reference laboratories nationwide.
  • Engaged Dr. Robin Robinson as a strategic advisor to aid in commercialization of the T2Biothreat Panel.
  • A live and recorded webcast of the call will be available on the “Investors” section of the Company’s website at www.t2biosystems.com .

bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Montag, April 1, 2024
Medical Devices, Surgery, FDA, Genetics, Clinical Trials, Biotechnology, Radiology, Pharmaceutical, Health, Oncology, Research, Lung cancer, Growth, CFO, Laboratory developed test, Form, Patient, Accounting, Bronchoalveolar lavage, Sale, Acquisition, Cancer, CPA, CAP, Insurance, MBA, Lung, BAL, BIAF, Bronchoscopy, LDT, Optimism, Medicare, Calendar, Marketing, CMS, Physician, Pharmaceutical industry

Revenue for the fourth quarter of 2023 was approximately $2.2 million, up from no revenue for the prior-year period.

Key Points: 
  • Revenue for the fourth quarter of 2023 was approximately $2.2 million, up from no revenue for the prior-year period.
  • Research and development expenses were $432,000 for the fourth quarter of 2023, compared with $429,000 for the comparable period in 2022.
  • Selling, general and administrative expenses were $2.2 million for the fourth quarter of 2023, compared with $1.2 million for the comparable period in 2022.
  • Net loss for the fourth quarter of 2023 was $2.4 million, compared with a net loss of $1.7 million for the comparable period in 2022.

Bridging Cultures: Boao Forum's Sub-Forum on Religious Harmony Sparks Global Buddhist Dialogue

Retrieved on: 
Montag, April 1, 2024
Religion, Conference, Chinese Buddhism, History, Growth, Executive Council, Kingdom, Compassion, LDT, Boao Forum for Asia, Gangaramaya Temple, Multimedia, YAN, Pure land, BFA, National Assembly, CCRP, YIN, Wisdom, Tourism

QIONGHAI, China, April 1, 2024 /PRNewswire/ -- The Sub-forum on Religious Harmony and Mutual Learning Among Civilizations took place at the Boao Forum for Asia (BFA) Annual Conference 2024 by March 29.

Key Points: 
  • QIONGHAI, China, April 1, 2024 /PRNewswire/ -- The Sub-forum on Religious Harmony and Mutual Learning Among Civilizations took place at the Boao Forum for Asia (BFA) Annual Conference 2024 by March 29.
  • The Minister of Religious Affairs of Cambodia, Chay Borin, attended the event as a special guest.
  • Let us remain steadfast in promoting harmonious development and cooperation between the East and the West as we move forward."
  • He highlighted the positive impact of Buddhist principles such as compassion, peace, the Middle Way, and consummate interfusion in addressing the shared challenges humanity faces today.